# US 11,999,796 B2 · Anti-CD70 chimeric antigen receptors

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 11,999,796 B2
- Document ID: US11999796B2
- Status: Granted
- Kind: B2
- Application number: 16/906,061
- Filed: 2020-06-19
- Published: 2020-10-08
- Granted: 2024-06-04
- Earliest claimed: 2014-12-08
- Assignees: The United States of America, as represented by the Secretary, Department of Health and Human Services
- Applicants: The United States of America,as represented by the Secretary, Department of Health and Human Services
- Inventors: Qiong J. Wang; Zhiya Yu; James C. Yang
- Web page: https://patentgrep.com/patent/US11999796B2

## CPC

- C07K 16/30: from tumour cells
- A61K 40/11: T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
- A61K 40/31: Chimeric antigen receptors [CAR]
- A61K 40/4232: {Tumor necrosis factors [TNF] or CD70}
- A61P 35/00: Antineoplastic agents
- C07K 14/7051: {T-cell receptor (TcR)-CD3 complex}
- C07K 14/70517: {CD8}
- C07K 14/70521: {CD28, CD152}
- C07K 14/70578: {NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95 (NGF-receptor C07K14/71, TNF-receptor C07K14/7151)}
- C07K 14/7153: {for colony-stimulating factors [CSF]}
- C07K 16/2875: {against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154 (against NGF C07K16/22, against TNF C07K16/241)}
- A61K 35/17: Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes (when activated by a specific antigen A61K39/00)
- A61K 2239/38: characterised by the dose, timing or administration schedule
- A61K 2239/57: Skin; melanoma
- C07K 2317/60: characterized by non-natural combinations of immunoglobulin fragments
- C07K 2317/622: Single chain antibody (scFv)
- C07K 2319/00: Fusion polypeptide
- C07K 2319/02: containing a signal sequence
- C07K 2319/03: containing a transmembrane segment
- C07K 2319/33: fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The invention provides a chimeric antigen receptor (CAR) having antigenic specificity for CD70, the CAR comprising: an antigen binding—transmembrane domain comprising a CD27 amino acid sequence lacking all or a portion of the CD27 intracellular T cell signaling domain; a 4-1BB intracellular T cell signaling domain; a CD3ζ intracellular T cell signaling domain; and optionally, a CD28 intracellular T cell signaling domain. Nucleic acids, recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions relating to the CARs are disclosed. Methods of detecting the presence of cancer in a mammal and methods of treating or preventing cancer in a mammal are also disclosed.

## Claims

### Claim 1

A chimeric antigen receptor (CAR) having antigenic specificity for CD70, wherein the CAR comprises the amino acid sequence of SEQ ID NO: 12, and wherein CD70 comprises the amino acid sequence of SEQ ID NO: 1.

### Claim 2 (depends on 1)

A nucleic acid comprising a nucleotide sequence encoding the CAR of claim 1.

### Claim 3

A nucleic acid comprising a nucleotide sequence encoding a chimeric antigen receptor (CAR) having antigenic specificity for CD70, wherein the nucleic acid comprises the nucleotide sequence of SEQ ID NO: 19, and wherein CD70 comprises the amino acid sequence of SEQ ID NO: 1.

### Claim 4 (depends on 3)

A recombinant expression vector comprising the nucleic acid of claim 3.

### Claim 5 (depends on 4)

An isolated host cell comprising the recombinant expression vector of claim 4.

### Claim 6 (depends on 5)

A population of host cells comprising two or more host cells of claim 5.

### Claim 7 (depends on 1)

A pharmaceutical composition comprising (i) the CAR of claim 1, (ii) a nucleic acid comprising a nucleotide sequence encoding the CAR of (i), (iii) a recombinant expression vector comprising the nucleic acid of (ii), (iv) a host cell comprising the recombinant expression vector of (iii), or (v) a population of host cells comprising two or more host cells of (iv), and a pharmaceutically acceptable carrier.